EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma

Yuko Matsuo, Kenji Ashida iD, Ayako Nagayama, Kanoko Moritaka, Mizuki Gobaru, Junichi Yasuda, Naoyuki Ogasawara, Hirofumi Kurose, Katsuaki Chikui, Shimpei Iwata, Yukihiro Inoguchi, Nao Hasuzawa und 3 weitere

Endocrine Oncology · 30.08.2023 · 3 (1)

DOI: 10.1530/eo-23-0006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, erschienen am 30.08.2023. Verfasst von Yuko Matsuo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume, Fukuoka, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Metyrosine (alpha-methyl-para-tyrosine) effectively reduces catecholamine levels in patients with pheochromocytoma/paraganglioma. However, improvements in physiological and metabolic parameters and changes in endocrine function associated with metyrosine administration should be validated in comparison to surgery. This study was performed to confirm the effects of metyrosine on the physiological, metabolic, and endocrinological functions of patients with pheochromocytoma/paraganglioma in the perioperative period.

Design

This retrospective cohort study was performed at a single university hospital.

Methods

We included ten patients with pheochromocytoma/paraganglioma who received oral metyrosine after α-blocker therapy and consecutive surgeries. Urinary catecholamine metabolite levels and other clinical parameters were evaluated before and after metyrosine administration, and 1 week after surgery.

Results

The mean age was 53.1 ± 16.1 years. Of the ten participants (four men and six women), nine had pheochromocytoma and one had paraganglioma. The median maximum metyrosine dose was 750 mg/day. Urinary catecholamine metabolite levels significantly decreased in a dose-dependent manner after metyrosine administration. Both systolic and diastolic blood pressure significantly decreased after metyrosine and surgical treatment. Metyrosine administration significantly improved insulin sensitivity, although surgery improved the the basal insulin secretion. Additionally, serum prolactin and thyroid-stimulatory hormone levels were significantly increased by metyrosine treatment, whereas plasma renin activity was decreased.

Conclusions

Metyrosine significantly reduced catecholamines in patients with pheochromocytoma/paraganglioma and ensured the safety of the surgery. Adjustment of metyrosine administration may make surgical pretreatment more effective in achieving stabilized blood pressure and improving glucose metabolism. Endocrine parameters may manifest as the systemic effects of metyrosine administration.

Schlagwörter

Stichwörter der Autor:innen

diabetes mellitusdopamineparagangliomapheochromocytomaprolactin

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi, Kurume, Fukuoka, Japan.
  • Department of Urology, Kurume University School of Medicine, Asahi-machi, Kurume, Fukuoka, Japan.

ORCID-Profile: Kenji Ashida

Zitieren

APA

Matsuo, Y., Ashida, K., Nagayama, A., Moritaka, K., Gobaru, M., Yasuda, J., Ogasawara, N., Kurose, H., Chikui, K., Iwata, S., Inoguchi, Y., Hasuzawa, N., Motomura, S., Igawa, T., & Nomura, M. (2023). Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma. Endocrine Oncology, 3(1). https://doi.org/10.1530/eo-23-0006

Vancouver

Matsuo Y, Ashida K, Nagayama A, Moritaka K, Gobaru M, Yasuda J, et al. Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma. Endocrine Oncology. 2023;3(1). doi:10.1530/eo-23-0006

BibTeX
@article{Matsuo2023,
  author = {Matsuo, Yuko and Ashida, Kenji and Nagayama, Ayako and Moritaka, Kanoko and Gobaru, Mizuki and Yasuda, Junichi and Ogasawara, Naoyuki and Kurose, Hirofumi and Chikui, Katsuaki and Iwata, Shimpei and Inoguchi, Yukihiro and Hasuzawa, Nao and Motomura, Seiichi and Igawa, Tsukasa and Nomura, Masatoshi},
  title = {Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma},
  journal = {Endocrine Oncology},
  year = {2023},
  volume = {3},
  number = {1},
  doi = {10.1530/eo-23-0006}
}
Kostenlos starten →